MarketLens

What Did the Recent CARVYKTI Data Reveal About Its Potential

3 months ago

SHARE THIS ON:

What Did the Recent CARVYKTI Data Reveal About Its Potential

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

What Did Legend Biotech's Investor Event Reveal About CARVYKTI

What Did Legend Biotech's Investor Event Reveal About CARVYKTI

3 months ago

What Did Bunge's 2026 Investor Day Reveal About Its Future

What Did Bunge's 2026 Investor Day Reveal About Its Future

6 months ago

What Did Skillsoft's Q4 FY2026 Earnings Reveal About Its Trajectory

What Did Skillsoft's Q4 FY2026 Earnings Reveal About Its Trajectory

5 months ago

What Do Summit Therapeutics' Q4 Results Reveal About Its Financial Health

What Do Summit Therapeutics' Q4 Results Reveal About Its Financial Health

6 months ago

Category

Top Featured Pro Only Stock Analysis Investment Ideas ETFs Crypto

You may also like

Stock News•2 weeks ago

Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

Immatics N.V. was downgraded to "Buy" from "Strong Buy" after a partial partnership termination, with its thesis hinging on anzu-cel phase 3 SUPRAME data in H1 2027. Phase 1b results showed 56% cORR a...

Stock News•1 months ago

Legend Biotech: Why I'm Ready To Go Long Again

Carvykti sales rose 10.1% QoQ and 49.7% YoY to $657M in Q2, after J&J reported continued strong demand for the CAR-T therapy. Legend Biotech could beat consensus estimates when it reports Q2 results.

Stock News•1 months ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

J&J's TECVAYLI + TALVEY cut disease progression/death risk by 89% and death risk by 62% in earlier-line RRMM, per Phase 3 MonumenTAL-6 trial results.

Breaking News

Biotech & Pharma

Corporate Earnings

Diversification

Event-Driven Investing

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

1 months ago

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

1 months ago

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

1 months ago

Top Headlines

Stock News•1 hour ago

$10,000 in Tesla When It Joined the S&P 500 Would Be About $15,700 Today. An Index Fund Would Have Done Better.

Stock News•4 hours ago

J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion

Stock News•5 hours ago

Google's Historic 396 MW Clean Energy Deal Just Changed the Game for 1 AI Power Play

Stock News•6 hours ago

Better AI Chip Stock: Broadcom vs. Nvidia

Stock News•6 hours ago

Dell Technologies Sees AI Boom Building as $95B Server Backlog Signals Demand